GLGangjun Lei

Gangjun Lei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gangjun Lei has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity

    by Bin-Jin Hwang, Erika J. Crosby, David T. Severson, Timothy N. Trotter, Jason McBane, Li-Chung Tsao, Tao Wang, Cong-Xiao Liu, Xiao-Yi Yang, Gangjun Lei, et al.

    Tumor antigen vaccination represents an appealing approach for cancer but has failed to materialize as oncologic standard of care. To understand long-term vaccine efficacy, we conducted a retrospective analysis of patients with human epidermal growth receptor 2 + (HER2 + ) breast cancer who received HER2-targeting vaccines and survived for >18 years. PBMC analysis revealed HER2-specific CD27 + memory CD4 and CD8 T cells, suggesting that CD27 signaling supports long-term immune memory. In human CD27 transgenic mice, combining HER2 vaccination with anti-CD27 agonism enhanced HER2-specific responses, particularly long-lived CD4 memory T cells. Murine models demonstrated ~40% tumor regression with combined therapy compared with vaccine alone (~6%). Additional scRNA-seq analysis identified CD4 T cells with a distinct gene expression profile, and depletion/adoptive transfer studies validated that CD4 T cells were essential for this effect. These findings suggest that CD27 agonism enhances vaccine-induced antigen-specific CD4 T cell responses, enabling durable antitumor immunity not entirely dependent on CD8 T cells.


  • Open Access

    Vaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer

    by Robert D. Marek, Selena Halabi, Mu-En Wang, Jason McBane, Junping Wei, Tao Wang, Xiao Yang, Congxiao Liu, Gangjun Lei, Herbert Kim Lyerly, et al.

    Background/Objectives: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to target this axis, many of these fail due to the emergent expression of AR RNA splice variants, such as AR-V7, that can signal independently of ligand binding. Other therapies, such as vaccination against prostate-specific antigens, have achieved FDA approvals but have fallen short of being incorporated as standard-of-care therapies for advanced prostate cancer. This may be due to the elevated level of immunosuppression observed in prostate cancer, which remains largely refractory to immune checkpoint blockade. Methods: We developed a vaccine targeting AR-V7, a common isoform associated with treatment resistance, and demonstrated its ability to elicit AR-V7-specific immunity and enable anti-tumor responses against AR-V7+ cancers in subcutaneous tumor models. Results: Our studies also revealed that AR-V7 expression conferred an immune suppressive phenotype that was significant in a non-AR-dependent prostate cancer model. Notably, in this model, we found that vaccination in combination with enzalutamide, an AR antagonist, suppressed these aggressive immune suppressive cancers and resulted in enhanced survival in comparison to control vaccinated and enzalutamide-treated mice. While anti-PD-1 immune checkpoint inhibition (ICI) alone slowed tumor growth, the majority of vaccinated mice that received anti-PD-1 therapy showed complete tumor elimination. Conclusions: Collectively, these results validate the importance of AR signaling in prostate cancer immune suppression and suggest the potential of AR-V7-specific vaccines as therapeutic strategies against prostate cancer, offering significant protective and therapeutic anti-tumor responses, even in the presence of androgen signaling inhibitors.


  • Open Access

    FIGURE 2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

    by Timothy N. Trotter, Andrea Wilson, Jason McBane, Carina E. Dagotto, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Hannah Thrash, Joshua C. Snyder, Herbert Kim Lyerly, et al.

    Mutant GFP and luciferase induce immune responses comparable with wild-type (WT) proteins. A, WT male Balb/c mice were vaccinated with Ad encoding WT or mutant copies of GFP (ΔT64; n = 5/group) and serum antibody responses were measured after 3 weeks. Mice showed equivalent anti-GFP responses whether vaccinated with WT or mutant GFP. B, WT female C57Bl/6 mice were vaccinated with Ad-GFP-Luc WT or Ad-Luc mutant (G315A; n = 5/group) and serum antibody responses were measured after 3 weeks revealing similar levels of anti-Luc antibodies. P values for A, B are at 1:50 dilution by two-way ANOVA with Tukey multiple comparisons test. C, Male WT Balb/c mice were vaccinated with Ad encoding WT or mutant GFP (ΔT64) or Luc (H245R) and anti-GFP or -Luc T-cell responses in the spleens were detected after 3 weeks via ELISpot. Both WT and mutant forms of GFP and Luc were able to elicit robust T-cell responses compared with mice naïve for the respective antigen. P values were determined by two-way ANOVA with Tukey post hoc analysis. D, E0771 GFP-Luc cells were implanted in MFPs of female WT C57Bl/6 mice and were vaccinated with Ad encoding WT GFP, mutant GFP (ΔT64), WT Luc, mutant Luc (ΔH245), or LacZ control (n = 5 per group) after three days. Compared with LacZ control vaccination, GFP WT/mutant, or Luc WT/mutant vaccines resulted in a comparable reduction in tumor growth. P values are at time of euthanasia by two-way ANOVA with Tukey multiple comparisons test. All P values represent mean ± SEM.

  • Open Access

    Figure S2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

    by Timothy N. Trotter, Andrea Wilson, Jason McBane, Carina E. Dagotto, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Hannah Thrash, Joshua C. Snyder, Herbert Kim Lyerly, et al.

    Validating mutant GFP and Luc activity in Adenovirus vaccines

  • Open Access

    FIGURE 7 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

    by Timothy N. Trotter, Andrea Wilson, Jason McBane, Carina E. Dagotto, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Hannah Thrash, Joshua C. Snyder, Herbert Kim Lyerly, et al.

    Summary of tumor behavior in differentially tolerant animal models. A, Xenoantigen-bearing tumor cells implanted orthotopically into immune-deficient mice typically grow and metastasize as expected and can be easily observed with fluorescence/bioluminescence. B, Conversely, in immune-competent animals the presence of foreign immunogens often results in complete rejection of the primary tumor, or severely restricts expression of immunogenic antigens and limits the utility of reporter proteins. C, However, NoGlow mice are tolerant to foreign GFP, Luciferase, and rtTA, thus allowing primary tumor growth and de novo metastasis of xenoantigen-expressing tumor cells.

  • Open Access

    Figure S3 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

    by Timothy N. Trotter, Andrea Wilson, Jason McBane, Carina E. Dagotto, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Hannah Thrash, Joshua C. Snyder, Herbert Kim Lyerly, et al.

    Validating the NoGlow construct in vitro

  • Open Access

    Figure S2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

    by Timothy N. Trotter, Andrea Wilson, Jason McBane, Carina E. Dagotto, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Hannah Thrash, Joshua C. Snyder, Herbert Kim Lyerly, et al.

    Validating mutant GFP and Luc activity in Adenovirus vaccines

  • Open Access

    FIGURE 2 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

    by Timothy N. Trotter, Andrea Wilson, Jason McBane, Carina E. Dagotto, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Hannah Thrash, Joshua C. Snyder, Herbert Kim Lyerly, et al.

    Mutant GFP and luciferase induce immune responses comparable with wild-type (WT) proteins. A, WT male Balb/c mice were vaccinated with Ad encoding WT or mutant copies of GFP (ΔT64; n = 5/group) and serum antibody responses were measured after 3 weeks. Mice showed equivalent anti-GFP responses whether vaccinated with WT or mutant GFP. B, WT female C57Bl/6 mice were vaccinated with Ad-GFP-Luc WT or Ad-Luc mutant (G315A; n = 5/group) and serum antibody responses were measured after 3 weeks revealing similar levels of anti-Luc antibodies. P values for A, B are at 1:50 dilution by two-way ANOVA with Tukey multiple comparisons test. C, Male WT Balb/c mice were vaccinated with Ad encoding WT or mutant GFP (ΔT64) or Luc (H245R) and anti-GFP or -Luc T-cell responses in the spleens were detected after 3 weeks via ELISpot. Both WT and mutant forms of GFP and Luc were able to elicit robust T-cell responses compared with mice naïve for the respective antigen. P values were determined by two-way ANOVA with Tukey post hoc analysis. D, E0771 GFP-Luc cells were implanted in MFPs of female WT C57Bl/6 mice and were vaccinated with Ad encoding WT GFP, mutant GFP (ΔT64), WT Luc, mutant Luc (ΔH245), or LacZ control (n = 5 per group) after three days. Compared with LacZ control vaccination, GFP WT/mutant, or Luc WT/mutant vaccines resulted in a comparable reduction in tumor growth. P values are at time of euthanasia by two-way ANOVA with Tukey multiple comparisons test. All P values represent mean ± SEM.

  • Open Access

    Figure S1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

    by Timothy N. Trotter, Andrea Wilson, Jason McBane, Carina E. Dagotto, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Hannah Thrash, Joshua C. Snyder, Herbert Kim Lyerly, et al.

    Additional E0771 tumor growth in WT, GH, and CAG Luc-GFP mice; MMTV CAG HER2 Ad-HER2 vaccination T cell responses.

  • Open Access

    FIGURE 1 from Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent “NoGlow” Mice

    by Timothy N. Trotter, Andrea Wilson, Jason McBane, Carina E. Dagotto, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Hannah Thrash, Joshua C. Snyder, Herbert Kim Lyerly, et al.

    Tolerance to foreign antigens is animal model specific. A and B, Mice expressing GFP and Luc in the pituitary (GH; n = 5), full-body GFP, and Luc (CAG Luc-GFP; n = 5), in FoxP3+ cells (Foxp3-GFP; n = 4), or wild-type (WT) C57Bl/6 (n = 4) were vaccinated with adenovirus (Ad) encoding GFP/Luc (2.6 × 1010 vp/mouse) and anti-Luciferase (A) or anti-GFP (B) in the serum were evaluated by ELISA after 2 weeks. Only CAG Luc-GFP animals, which express both GFP and Luc, display humoral tolerance to both upon vaccination. P values shown are at 1:50 dilution by two-way ANOVA with Tukey multiple comparisons test. C and D, E0771 GFP-Luc cells were implanted into the MFP of female WT C57Bl/6, GH, or CAG Luc-GFP mice (n = 10 each) and subsequently vaccinated with Ad-GFP/Luc or Ad-LacZ as control on day 3 (n = 5/group each). Growth of individual tumors for the duration of the experiment (C) or average tumor volume until time of first euthanasia (D) comparing control or antigen-specific Ad demonstrate that E0771 GFP-Luc cells grow significantly larger in tolerant CAG Luc-GFP mice. P values shown are at day of first euthanasia by two-way ANOVA with Bonferroni multiple comparisons test. E, Female WT (n = 3) or mice expressing human HER2 under the whey acid protein (WAP) promoter (WAP HER2; n = 5) or MMTV Cre–driven CAG promoter (MMTV CAG HER2; n = 3) were vaccinated with Ad-Human Her2 and splenocytes were analyzed for anti-HER2 responses by ELISPOT after 3 weeks. WAP HER2 mice displayed reduced anti-HER2 responses compared with WT animals; however, MMTV CAG HER2 animals produced a limited anti-HER2 T-cell response compared with both WT and WAP HER2. Groups were compared by two-way ANOVA with Tukey multiple comparisons test. F, Doxycycline-inducible GFP animals were given doxycycline (dox)-containing chow at the indicated time points, vaccinated at 9 weeks old, and euthanized after two weeks. G, Serum anti-GFP responses in animals from F reveal that GFP remains highly immunogenic in mice with late (8 weeks old) versus early (4 weeks old/at birth) expression of GFP via doxycycline. P values shown are at 1:50 dilution by two-way ANOVA with Tukey post hoc analysis. All P values represent mean ± SEM.